Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) CEO David Elsley joined Steve Darling from Proactive to share news the company has been granted authorization by the U.S. Food and Drug Administration for the Company's Investigational New Drug Application in relation to CardiolRx. Elsley telling Proactive this will allow the company to begin a Phase II open-label pilot study designed to evaluate the tolerance and safety of CardiolRx is use for Recurrent pericarditis.
Cardiol Therapeutics gets FDA go ahead for Investigational New Drug Application for CardiolRx
